Navigation Links
Cancer research partnership between UCSF, MMRF to drive drug development
Date:5/29/2009

The University of California, San Francisco (UCSF) and the Multiple Myeloma Research Foundation (MMRF) have established the Stephen and Nancy Grand Multiple Myeloma Translational Initiative, a research collaboration dedicated to translating basic science discoveries into new candidate drugs for testing in clinical trials.

The initiative, known as MMTI, was launched with a $2 million gift from Stephen and Nancy Grand of San Francisco. Mr. Grand, age 65, is a multiple myeloma patient at the UCSF Helen Diller Family Comprehensive Cancer Center.

The MMTI, a collaboration comprised of UCSF basic scientists, clinical researchers and clinicians, will be led by Jeffrey Wolf, MD, director of the Multiple Myeloma Program at the UCSF Helen Diller Family Comprehensive Cancer Center. The basic science research arm will be led by UCSF's Peter Walter, PhD, an investigator with the Howard Hughes Medical Institute and the lead scientist on a Collaborative Innovation Award from HHMI that will help drive the initiative.

"Through the MMRF's drive to identify barriers slowing drug discovery and development, we saw a critical need to champion the growth of translational research in multiple myeloma," said Louise M. Perkins, PhD, chief scientific officer of the MMRF. "By partnering with UCSF to create the business plan for the MMTI, we are enabling the more rapid development of the next generation of treatments for multiple myeloma, and providing a blueprint for translational initiatives that can serve as models for advancing research in other cancers and diseases."

Multiple myeloma is an incurable cancer of the bone marrow. The five-year relative survival rate is about 38 percent, one of the lowest of all cancers. In 2008, an estimated 19,920 adults -- 11,190 men and 8,730 women -- in the United States were diagnosed with multiple myeloma and an estimated 10,690 people died from the disease.

"Although we have made much progress in delivering new treatment options to patients, multiple myeloma remains very difficult to treat and effective treatment options are limited," said Wolf. "By bringing to bear the expertise of UCSF in partnership with the MMRF, we are confident that the MMTI will hasten the pace at which new therapies to treat the disease are developed."

UCSF is at the forefront in advancing translational research, which is recognized as the critical weak link in medical science today. It involves moving discoveries made in the lab through the process of animal studies, animal testing and small-scale human trials to determine if a discovery warrants examination on a larger scale by a biotechnology or pharmaceutical company.

Research universities have excelled at discovering the genes and proteins and other cellular and extracellular components that underlie disease processes, but they have not had the infrastructure to investigate the potential of these components as therapeutic targets or tools. The work requires close collaboration between basic researchers, clinical researchers and clinicians.

In 2006, UCSF received a five-year, $100 million grant from the National Institutes of Health to support further development of the UCSF infrastructure for translational medicine. UCSF's existing infrastructure will enable the MMTI to begin its research efforts immediately.

"Currently, there are few translational research initiatives focused solely on multiple myeloma, so we are especially proud to support the MMRF and UCSF, and we are grateful to HHMI for its help in supporting such exciting, important science," said Stephen Grand, an MMRF board member. "The MMTI provides new hope for patients whose treatment options are limited, by enabling the swifter development of new drug candidates and increasing access to promising therapies under investigation."


'/>"/>

Contact: Jennifer OBrien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
2. Falcon Genomics Awarded Patent for Innovative Cancer Test
3. Cancer cells need normal, nonmutated genes to survive
4. The vulnerable cancer cell
5. New survey highlights growing concern about risk of infection in cancer patients
6. Cancer Survivors Can Still Be Fit, Study Asserts
7. New blood test greatly reduces false-positives in prostate cancer screening
8. Cardiovascular fitness not affected by cancer treatment
9. Cottonseed-based drug shows promise in treating severe brain cancer
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... luxurious collection of unique masks and serums that perfectly fuse the beauty of ... advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th in ...
(Date:8/22/2017)... ... 2017 , ... The old adage “you are what you ... healthy foods. But this well-known piece of nutrition advice ignores that an individual’s ... not only on properties of the food but also on properties of the ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... cycle management (RCM) solutions, announced recently the availability of a new professional fee ... in appreciation for their service to the healthcare industry. E/M coding is complex ...
(Date:8/22/2017)... DFW Metroplex, TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is ... They provide repair and replacement of auto glass for most makes and models, in ... area in the USA. , They have been a family owned business for the ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
Breaking Medicine Technology: